Citations

Clear

1434 citation(s) found for "Uk, Nathan".

Abstract 4996: Axl inhibition sensitizes cholangiocarcinoma cells to cytotoxic chemotherapy
Takaichi, Shohei , Carlson, Danielle M. , Daher, Alaa Abou , Werneburg, Nathan W., Wu, Xinyan , Mun, Dong‐Gi , Tomlinson, Jennifer L. , Abdelrahman, Amro M. , Carlson, Danielle Marie , Pandey, Akhilesh , Gores, Gregory J. , Smoot, Rory L.

Mayo Clinic

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 4996-4996

10.1158/1538-7445.am2023-4996 Get It

Abstract Background: Cholangiocarcinoma (CCA) is a lethal disease with limited therapeutic options. We have previously discovered LCK driving signaling through AXL, a TAM receptor tyrosine kinase (RTK), by phosphoproteomic analysis of CCA (J Hepatol 2022). AXL mediates acquired drug resistance in solid cancers. However, the exact role of AXL in CCA still remains to be elucidated. Here, we investigated the significance of AXL expression as a potential therapeutic target in CCA and the role of phosphorylated AXL Y866. Methods: We first evaluated the expression levels of AXL in CCA and its associations with patient outcomes using The Cancer Genome Atlas (TCGA) database. Next, to evaluate whether AXL inhibition sensitizes CCA cells to gemcitabine and cisplatin (GemCis) therapy, AXL downregulation was achieved via the siRNA approach and the selective inhibitor bemcentinib. We examined the 50% inhibitory concentration (IC50) value of HuCCT1, a well-characterized CCA cell line, on GemCis therapy with or without AXL knockdown using cell viability assay. Then we assessed the efficacy of the combinatorial therapy of GemCis and bemcentinib utilizing Calcusyn software. Apoptosis was evaluated by Annexin V assay. In vivo efficacy was assessed using an SB-1 (murine CCA cell line) and a syngeneic murine model of CCA treated with vehicle, GemCis, bemcentinib, and the combination of GemCis and bemcentinib. Finally, to investigate the role of AXL Y866 in CCA, we performed BioID to identify and compare the interactomes of AXL WT and AXL Y866F in HuCCT1 cells. Results: In the TCGA cohorts, AXL is significantly expressed in CCA (P < 0.01), and disease-free survival and overall survival in the low AXL expression group are significantly longer than those in the high AXL expression group (P = 0.04, 0.01). In in vitro study, the IC50 value of GemCis was decreased from 685nM to 129nM after AXL knockdown. A synergistic effect was observed with CI = 0.17 and Fa = 0.50 in the combinatorial therapy. The combinatorial therapy caused significantly increased apoptosis compared to GemCis or bemcentinib alone (P < 0.01, P < 0.01). In in vivo study, the combinatorial therapy significantly suppressed the tumor growth compared to GemCis or bemcentinib alone (P = 0.04, 0.01), and the expression levels of Ki67 and the phosphorylation levels of PEAK1 decreased in the combinatorial therapy group compared to other groups in immunostaining examination. In BioID experiments, among the 222 proteins detected in both AXL WT and AXL Y866F interactomes, PEAK1 kinase, which localizes to actin cytoskeleton and focal adhesions, was the kinase most affected by AXL Y866. In gene ontology analysis to characterize the interactome of AXL Y866, cell-cell adhesion and focal adhesion-related proteins were enriched. Conclusions: AXL inhibition sensitizes CCA cells to cytotoxic chemotherapy in the preclinical model. AXL Y866-PEAK1 signaling axis is a potential target for the treatment of CCA. Citation Format: Shohei Takaichi, Dong-Gi Mun, Jennifer L. Tomlinson, Amro M. Abdelrahman, Danielle M. Carlson, Alaa Abou Daher, Nathan W. Werneburg, Xinyan Wu, Akhilesh Pandey, Gregory J. Gores, Rory L. Smoot. Axl inhibition sensitizes cholangiocarcinoma cells to cytotoxic chemotherapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4996.
Abstract 814: Novel strategy for aptamer-directed nanovesicle targeting in cholangiocarcinoma
Yu, Mincheng , Loeuillard, Emilien , Watkins, Ryan , Takaichi, Shohei , Werneburg, Nathan W., Carlson, Danielle M. , Yang, Jingchun, Smoot, Rory L., Tomlinson, Jennifer L. , Conboy, Caitlin B. , Alva‐Ruiz, Roberto , Abdelrahman, Amro, Carlson, Danielle Marie , Yang, Jingchun, Ilyas, Sumera I. , Gores, Gregory J. , Patel, Tushar

Mayo Clinic

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 814-814

10.1158/1538-7445.am2023-814 Get It

Abstract Background: Cholangiocarcinoma (CCA) is a heterogeneous malignancy arising from the biliary epithelium. Its diverse molecular landscape and aggressive biology render many anti-cancer therapies ineffective. Nanovesicle technology provides an opportunity for therapeutic inhibition of oncogenic targets that have been previously classified as undruggable. EpCAM is an epithelial-specific, transmembrane glycoprotein with increased expression in human and murine CCA which can be used for nanovesicle targeting. As a proof of concept study, we designed and validated a novel strategy to direct therapeutic milk-derived nanovesicles (tMNVs) to CCA tumors. Methods: tMNVs were decorated with RNA nanoparticles containing a validated aptamer (EpDT3) against EpCAM conjugated to a cholesterol-triethylene-glycol (TEG) scaffold containing an Alexa647 fluorophore. Human and murine CCA cell lines were treated with aptamer directed tMNVs and assessed for nanovesicle uptake by fluorescent microscopy. CCA tumor tissue, derived from orthotopic implantation of a syngeneic CCA cell line, SB1, into a C57BL/6 mouse, was collected and treated with either aptamer-directed or bare tMNVs ex vivo, and compared with adjacent normal liver tissue. Flow cytometry was utilized to characterize tMNVs absorption profile. C57BL/6 mice who had previously undergone SB1 orthotopic and flank implantation were treated with aptamer-directed tMNVs by tail-vein injection and subsequently euthanized. Tissue was collected for biodistribution analyses by fluorescent microscopy. The experiment was repeated in NOD-scid mice following orthotopic implantation of patient derived xenograft (PDX) CCA tumor. Results: Both human and murine CCA cells treated with aptamer-directed tMNVs demonstrated high fluorescent signal consistent with tMNV absorption within 12 hours of application. Flow cytometry analysis showed aptamer-directed tMNVs were absorbed at a higher proportion by CCA tumors than bare tMNVs ex vivo. Aptamer-directed tMNVs also had better absorption by CCA tumors compared to adjacent normal liver tissue. Following treatment with aptamer-directed or bare tMNVs in vivo, fluorescent microscopy demonstrated that aptamer-directed tMNVs were significantly better absorbed in the orthotopic SB1 tumors, followed by the subcutaneous tumors. Minimal fluorescent signal was noted in the normal adjacent liver. Orthotopically implanted PDX tumors also demonstrated high fluorescent signals following intravenous treatment with aptamer-directed tMNVs. Conclusions: Utilizing a novel targeting strategy, we were able to design tMNVs capable of reliably and specifically targeting CCA in preclinical models. This work is foundational to the future application of nanovesicle technology in the CCA treatment paradigm. Citation Format: Mincheng Yu, Jennifer L. Tomlinson, Emilien J. Loeuillard, Ryan D. Watkins, Caitlin B. Conboy, Shohei Takaichi, Nathan W. Werneburg, Roberto Alva-Ruiz, Amro Abdelrahman, Danielle M. Carlson, Jingchun Yang, Sumera I. Ilyas, Gregory J. Gores, Tushar Patel, Rory L. Smoot. Novel strategy for aptamer-directed nanovesicle targeting in cholangiocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 814.
Utilization and reimbursement trends of osteopathic manipulative treatment for Medicare patients: 2000–2019
Starr, Evan G. , Hanson, Romney B. , Woolstenhulme, Jonathan B. , Roush, Andrew J. , Sperry, Nathan B., Wilde, Benjamin, Zapata, Isain , Smith, Jacob F. , Brooks, Amanda E.

Mayo Clinic

Journal of Osteopathic Medicine | March 30, 2023 | Volume: 123 | Issue: 6 | Pages: 309-315

10.1515/jom-2022-0174 | PMID 36996336 Get It

Abstract Context Osteopathic manipulative treatment (OMT) has been established as a beneficial and noninvasive treatment option for multiple conditions. With the total number of osteopathic providers tripling and the subsequent increase in osteopathic physician representation, we would expect the clinical use of OMT to increase accordingly. Objectives To that end, we evaluated the utilization and reimbursement of OMT services among Medicare beneficiaries. Methods Current procedural terminology (CPT) codes 98925 to 98929 were accessed from the Center for Medicare and Medicaid Services (CMS) from 2000 to 2019. These codes indicate OMT treatment, 98925 (1–2 body regions treated), 98926 (3–4 body regions treated), 98927 (5–6 body regions treated), 98928 (7–8 body regions treated), and 98929 (9–10 body regions treated). Monetary reimbursement from Medicare was adjusted for inflation, and total code volume was scaled to codes per 10,000 beneficiaries to account for the increase in Medicare enrollment. Results Overall OMT utilization declined between 2000 and 2019 by 24.5%. A significant downward trend in the utilization of CPT codes for OMT involving fewer body regions (98925–98927) was observed, and was contrasted by a slight upward trend in the use of codes for more body regions (98928, 98929). The adjusted sum reimbursement of all codes decreased by 23.2%. Lower value codes showed a higher rate of decline, whereas higher value codes changed less dramatically. Conclusions We conjecture that lower remuneration for OMT has disincentivized physicians financially and may have contributed to the overall decline in OMT utilization among Medicare patients, along with a decreased number of residencies offering specific training in OMT, and increased billing complexity. In considering the upward trend of higher-value code usage, it is possible that some physicians are increasing the comprehensiveness of their physical assessment and associated OMT to reduce the overall financial impact of reimbursement cuts.
Whole Genome Analysis of Venous Thromboembolism: the Trans-Omics for Precision Medicine Program
Seyerle, Amanda A. , Laurie, Cecelia , Coombes, Brandon J. , Jain, Deepti , Conomos, Matthew P. , Brody, Jennifer A. , Chen, Ming‐Huei , Gogarten, Stephanie M. , Beutel, Kathleen M , Gupta, Namrata , Heckbert, Susan R. , Jackson, Rebecca D., Johnson, Andrew D. , McKnight, Barbara, Metcalf, Ginger , Morrison, Alanna C. , Reiner, Alex P. , Sofer, Tamar , Tang, Weihong , Program, Trans-Omics for Precision Medicine, Boerwinkle, Eric , Gabriel, Stacey , Gibbs, Richard A. , Laurie, Cathy C. , Rice, Kenneth , Pankow, James S. , Smith, Nicholas L. , Laurie, Cecelia A , Ko, Darae , Manson, JoAnn E , Metcalf, Ginger A , Morrison, Alanna C , Reiner, Alexander P , Sofer, Tamar , Tang, Weihong , Wiggins, Kerri L , Boerwinkle, Eric , de Andrade, Mariza , Laurie, Cathy C , Psaty, Bruce M , Vasan, Ramachandran S , Rice, Ken , Kooperberg, Charles , Pankow, James S , Smith, Nicholas L , Pankratz, Nathan , Brody, Jennifer A , Coombes, Brandon J , Rice, Kenneth , Manson, JoAnn E. , Wiggins, Kerri L. , Program, Trans-Omics for Precision Medicine, Andrade, Mariza de , Psaty, Bruce M. , Vasan, Ramachandran S. , Kooperberg, Charles , Pankratz, Nathan

Mayo Clinic

Circulation: Genomic and Precision Medicine | March 24, 2023 | Volume: 16 | Issue: 2 | Pages: No page available

10.1161/circgen.121.003532 | PMID 36960714 Get It

Background: Risk for venous thromboembolism has a strong genetic component. Whole genome sequencing from the TOPMed program (Trans-Omics for Precision Medicine) allowed us to look for new associations, particularly rare variants missed by standard genome-wide association studies. Methods: The 3793 cases and 7834 controls (11.6% of cases were individuals of African, Hispanic/Latino, or Asian ancestry) were analyzed using a single variant approach and an aggregate gene-based approach using our primary filter (included only loss-of-function and missense variants predicted to be deleterious) and our secondary filter (included all missense variants). Results: Single variant analyses identified associations at 5 known loci. Aggregate gene-based analyses identified only PROC (odds ratio, 6.2 for carriers of rare variants; P =7.4×10 −14 ) when using our primary filter. Employing our secondary variant filter led to a smaller effect size at PROC (odds ratio, 3.8; P =1.6×10 −14 ), while excluding variants found only in rare isoforms led to a larger one (odds ratio, 7.5). Different filtering strategies improved the signal for 2 other known genes: PROS1 became significant (minimum P =1.8×10 −6 with the secondary filter), while SERPINC1 did not (minimum P =4.4×10 −5 with minor allele frequency <0.0005). Results were largely the same when restricting the analyses to include only unprovoked cases; however, one novel gene, MS4A1 , became significant ( P =4.4×10 −7 using all missense variants with minor allele frequency <0.0005). Conclusions: Here, we have demonstrated the importance of using multiple variant filtering strategies, as we detected additional genes when filtering variants based on their predicted deleteriousness, frequency, and presence on the most expressed isoforms. Our primary analyses did not identify new candidate loci; thus larger follow-up studies are needed to replicate the novel MS4A1 locus and to identify additional rare variation associated with venous thromboembolism.
Intraoperatively Diagnosed Facial Schwannoma: A Multicenter Study of Incidence, Management, and Proposed Preoperative Imaging Protocol
Lewis, Daniel J. , Plitt, Aaron , Neff, Brian A., Hammerbeck-Ward, Charlotte , Driscoll, Colin L. W., Carlson, Matthew L. , Lloyd, Simon , Freeman, Simon , Potter, Gillian , Link, Michael J., Hannan, Cathal John , Lewis, Daniel, Richardson, George E. , King, Andrew Thomas , Gompel, Jamie J. Van , Pathmanaban, Omar Nathan , Link, Michael J. , Rutherford, Scott

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1761971 Get It

Migraine Patient Care Model Preferences in a Community Practice
Stern, Jennifer I. , Ebbert, Jon O. , Young, Nathan P. , Young, Nathan P , Vierkant, Robert A.

Mayo Clinic

Neurology Clinical Practice | March 19, 2023 | Volume: 13 | Issue: 2 | Pages: No page available

10.1212/cpj.0000000000200131 | PMID 37064592 Get It

Intraoperative diagnosis of facial schwannomas: a multicenter summation of clinical experience, preoperative avoidance, and intraoperative management protocol
Plitt, Aaron , Snyder, Lauren Rose, Hammerbeck-Ward, Charlotte , Neff, Brian A., Driscoll, Colin L. W., Carlson, Matthew L. , Lane, John I. , Lloyd, Simon , Freeman, Simon , Laitt, Roger, Abdulla, Sarah , Siripurapu, Rekha, Potter, Gillian , Link, Michael J., Rutherford, Scott , Plitt, Aaron R, Driscoll, Colin L., Lewis, Daniel , Hannan, Cathal John , Richardson, George E. , King, Andrew Thomas , Pathmanaban, Omar Nathan , Gompel, Jamie J. Van , Link, Michael J.

Mayo Clinic

Journal of Neurosurgery | March 17, 2023 | Volume: 139 | Issue: 4 | Pages: 972-983

10.3171/2023.2.jns222368 | PMID 36933255 Get It

OBJECTIVE Preoperative differentiation of facial nerve schwannoma (FNS) from vestibular schwannoma (VS) can be challenging, and failure to differentiate between these two pathologies can result in potentially avoidable facial nerve injury. This study presents the combined experience of two high-volume centers in the management of intraoperatively diagnosed FNSs. The authors highlight clinical and imaging features that can distinguish FNS from VS and provide an algorithm to help manage intraoperatively diagnosed FNS. METHODS Operative records of 1484 presumed sporadic VS resections between January 2012 and December 2021 were reviewed, and patients with intraoperatively diagnosed FNSs were identified. Clinical data and preoperative imaging were retrospectively reviewed for features suggestive of FNS, and factors associated with good postoperative facial nerve function (House-Brackmann [HB] grade ≤ 2) were identified. A preoperative imaging protocol for suspected VS and recommendations for surgical decision-making following an intraoperative FNS diagnosis were created. RESULTS Nineteen patients (1.3%) with FNSs were identified. All patients had normal facial motor function preoperatively. In 12 patients (63%), preoperative imaging demonstrated no features suggestive of FNS, with the remainder showing subtle enhancement of the geniculate/labyrinthine facial segment, widening/erosion of the fallopian canal, or multiple tumor nodules in retrospect. Eleven (57.9%) of the 19 patients underwent a retrosigmoid craniotomy, and in the remaining patients, a translabyrinthine (n = 6) or transotic (n = 2) approach was used. Following FNS diagnosis, 6 (32%) of the tumors underwent gross-total resection (GTR) and cable nerve grafting, 6 (32%) underwent subtotal resection (STR) and bony decompression of the meatal facial nerve segment, and 7 (36%) underwent bony decompression only. All patients undergoing subtotal debulking or bony decompression exhibited normal postoperative facial function (HB grade I). At the last clinical follow-up, patients who underwent GTR with a facial nerve graft had HB grade III (3 of 6 patients) or IV facial function. Tumor recurrence/regrowth occurred in 3 patients (16%), all of whom had been treated with either bony decompression or STR. CONCLUSIONS Intraoperative diagnosis of an FNS during a presumed VS resection is rare, but its incidence can be reduced further by maintaining a high index of suspicion and undertaking further imaging in patients with atypical clinical or imaging features. If an intraoperative diagnosis does occur, conservative surgical management with bony decompression of the facial nerve only is recommended, unless there is significant mass effect on surrounding structures.
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Schoen, Robert E. , Boardman, Lisa A. , Cruz‐Correa, Marcia , Bansal, Ajay , Kastenberg, David , Hur, Chin , Dzubinski, Lynda , Kaufman, Sharon F. , Rodriguez, Luz M. , Richmond, Ellen , Szabó, Éva , Salazar, Andres Μ. , McKolanis, John , Beatty, Pamela , Pai, Reetesh K. , Jacqueline, Camille M. , Bao, Riyue , Diergaarde, Brenda , Foster, Nathan R. , Zahrieh, David M. , Finn, Olivera J. , Umar, Asad , Szabo, Eva , Salazar, Andres , McKolanis, John , Beatty, Pamela , Pai, Reetesh K , Singhi, Aatur Dilip , Jacqueline, Camille M , Bao, Riyue , Diergaarde, Brenda , McMurray, Ryan P , Strand, Carrie A , Foster, Nathan R , Zahrieh, David , Limburg, Paul J , Finn, Olivera J , Richmond, Ellen S. , Boardman, Lisa , Schoen, Robert E , Cruz-Correa, Marcia , RODRIGUEZ, LUZ MARIA , McMurray, Ryan P. , Strand, Carrie , Limburg, Paul J.

Mayo Clinic

Clinical Cancer Research | March 9, 2023 | Volume: 29 | Issue: 9 | Pages: 1678-1688

10.1158/1078-0432.ccr-22-3168 | PMID 36892581 Get It

Abstract Purpose: To assess whether MUC1 peptide vaccine produces an immune response and prevents subsequent colon adenoma formation. Patients and Methods: Multicenter, double-blind, placebo-controlled randomized trial in individuals age 40 to 70 with diagnosis of an advanced adenoma ≤1 year from randomization. Vaccine was administered at 0, 2, and 10 weeks with a booster injection at week 53. Adenoma recurrence was assessed ≥1 year from randomization. The primary endpoint was vaccine immunogenicity at 12 weeks defined by anti-MUC1 ratio ≥2.0. Results: Fifty-three participants received the MUC1 vaccine and 50 placebo. Thirteen of 52 (25%) MUC1 vaccine recipients had a ≥2-fold increase in MUC1 IgG (range, 2.9–17.3) at week 12 versus 0/50 placebo recipients (one-sided Fisher exact P &lt; 0.0001). Of 13 responders at week 12, 11 (84.6%) responded to a booster injection at week 52 with a ≥2-fold increase in MUC1 IgG measured at week 55. Recurrent adenoma was observed in 31 of 47 (66.0%) in the placebo group versus 27 of 48 (56.3%) in the MUC1 group [adjusted relative risk (aRR), 0.83; 95% confidence interval (CI), 0.60–1.14; P = 0.25]. Adenoma recurrence occurred in 3/11 (27.3%) immune responders at week 12 and week 55 (aRR, 0.41; 95% CI, 0.15–1.11; P = 0.08 compared with placebo). There was no difference in serious adverse events. Conclusions: An immune response was observed only in vaccine recipients. Adenoma recurrence was not different than placebo, but a 38% absolute reduction in adenoma recurrence compared with placebo was observed in participants who had an immune response at week 12 and with the booster injection.